troglitazone has been researched along with Anti-GBM Disease in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haraguchi, K | 1 |
| Shimura, H | 1 |
| Onaya, T | 1 |
1 other study available for troglitazone and Anti-GBM Disease
| Article | Year |
|---|---|
Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)gamma activators.
Topics: Animals; Anti-Glomerular Basement Membrane Disease; Antibodies; Autoantibodies; CD8-Positive T-Lymph | 2003 |